Literature DB >> 9486416

Regulation of the expression of aminopeptidase A, aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 in renal carcinoma cells and renal tubular epithelial cells by cytokines and cAMP-increasing mediators.

A Kehlen1, B Göhring, J Langner, D Riemann.   

Abstract

Aminopeptidase (AP) A is a transmembrane type II molecule widely distributed in mammalian tissues. Since APA expression may be absent in renal cell carcinoma (RCC), it is possible that there is an altered regulation or other defect of APA upon malignant transformation of proximal tubular cells. However, investigations into the regulation of APA on tumour cells are rare. We report, for the first time, that both transforming growth factor-beta 1 (TGF-beta1) and tumour necrosis factor-alpha (TNF-alpha) down-regulate APA mRNA as well as protein expression in renal tubular epithelial cells and RCC cells in culture. In addition to this, both cytokines decrease dipeptidylpeptidase (DP) IV/CD26 mRNA, but not APN/CD13 mRNA expression. Otherwise, IL-4 and IL-13 increase CD13 as well as CD26 expression, but do not alter APA expression. Interferon-alpha (IFN-alpha), IFN-beta and IFN-gamma increase mRNA expression of all the three membrane ectopeptidases, whereas IL-1, IL-6, IL-7, IL-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been found to be without any significant effect. Treatment of cultured cells with cAMP-increasing agents, such as 8-bromo-cAMP or A23187, results in an increase in APA and DPIV/CD26, but no change in APN/CD13 mRNA expression or even a decrease in it. Furthermore, AP inhibitors can influence APA mRNA expression, since bestatin causes an increase in APA expression in a time- and dose-dependent manner, whereas bestatin does not change CD13 or CD26 expression. No difference could be found with respect to the modulation by different mediators between RCC cells and renal epithelial cells, though permanent tumour cell lines such as Caki-1 and Caki-2 may have lost some of the normally expressed peptidases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9486416      PMCID: PMC1904914          DOI: 10.1046/j.1365-2249.1998.00513.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

Review 1.  Prostaglandins and thromboxanes.

Authors:  B Samuelsson; M Goldyne; E Granström; M Hamberg; S Hammarström; C Malmsten
Journal:  Annu Rev Biochem       Date:  1978       Impact factor: 23.643

2.  Mechanism of cholera toxin action: covalent modification of the guanyl nucleotide-binding protein of the adenylate cyclase system.

Authors:  D Cassel; T Pfeuffer
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

3.  Serum transforming growth factor-beta1 in patients with renal cell carcinoma.

Authors:  H Wunderlich; T Steiner; U Junker; B Knöfel; A Schlichter; J Schubert
Journal:  J Urol       Date:  1997-05       Impact factor: 7.450

4.  Study on aminopeptidase A.

Authors:  Z Lojda; R Gossrau
Journal:  Histochemistry       Date:  1980

5.  Aminopeptidase a is a constituent of activated pericytes in angiogenesis.

Authors:  R O Schlingemann; E Oosterwijk; P Wesseling; F J Rietveld; D J Ruiter
Journal:  J Pathol       Date:  1996-08       Impact factor: 7.996

6.  Cytokines stimulate dipeptidyl peptidase-IV expression on human luteinizing granulosa cells.

Authors:  H Fujiwara; M Fukuoka; K Yasuda; M Ueda; K Imai; Y Goto; H Suginami; H Kanzaki; M Maeda; T Mori
Journal:  J Clin Endocrinol Metab       Date:  1994-10       Impact factor: 5.958

7.  Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice.

Authors:  S Mentzel; H B Dijkman; J P Van Son; R A Koene; K J Assmann
Journal:  J Histochem Cytochem       Date:  1996-05       Impact factor: 2.479

8.  Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell-derived cytokines, such as IL-4 and IL-13.

Authors:  D Riemann; A Kehlen; J Langner
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

9.  Rapid sequestration of DPP IV/CD26 and other cell surface proteins in an autophagic-like compartment in Caco-2 cells treated with forskolin.

Authors:  L Baricault; J A Fransen; M Garcia; C Sapin; P Codogno; L A Ginsel; G Trugnan
Journal:  J Cell Sci       Date:  1995-05       Impact factor: 5.285

10.  Inactivation of interleukin-8 by aminopeptidase N (CD13).

Authors:  N Kanayama; Y Kajiwara; J Goto; E el Maradny; K Maehara; K Andou; T Terao
Journal:  J Leukoc Biol       Date:  1995-01       Impact factor: 4.962

View more
  10 in total

Review 1.  Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.

Authors:  C Klemann; L Wagner; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-05-13       Impact factor: 4.330

2.  Possible contribution of aminopeptidase N (APN/CD13) to invasive potential enhanced by interleukin-6 and soluble interleukin-6 receptor in human osteosarcoma cell lines.

Authors:  A Kido; S Krueger; C Haeckel; A Roessner
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

3.  CD13 is dispensable for normal hematopoiesis and myeloid cell functions in the mouse.

Authors:  Beata Winnicka; Catherine O'Conor; Wolfgang Schacke; Kaitlyn Vernier; Christina L Grant; Fiona Hall Fenteany; Flavia E Pereira; Brannen Liang; Anupinder Kaur; Ran Zhao; David C Montrose; Daniel W Rosenberg; Hector L Aguila; Linda H Shapiro
Journal:  J Leukoc Biol       Date:  2010-04-29       Impact factor: 4.962

4.  Binding properties of a highly potent and selective iodinated aminopeptidase N inhibitor appropriate for radioautography.

Authors:  F Noble; N Luciani; S Da Nascimento; R Laï-Kuen; L Bischoff; H Chen; M C Fournié-Zaluski; B P Roques
Journal:  FEBS Lett       Date:  2000-02-04       Impact factor: 4.124

5.  Regulation of aminopeptidase N (EC 3.4.11.2; APN; CD13) by interferon-gamma on the HL-60 cell line.

Authors:  Jelka Gabrilovac; Davorka Breljak; Barbara Cupić; Andreja Ambriović-Ristov
Journal:  Life Sci       Date:  2005-04-22       Impact factor: 5.037

6.  ENPEP as a potential predictor of immune checkpoint inhibitor efficacy.

Authors:  Aoyun Wang; Han Chu; Zheng Jin; Zhihua Gong; Qingzhu Jia; Bo Zhu
Journal:  Cancer Med       Date:  2021-12-03       Impact factor: 4.452

7.  Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells.

Authors:  Mikio Terauchi; Hiroaki Kajiyama; Kiyosumi Shibata; Kazuhiko Ino; Akihiro Nawa; Shigehiko Mizutani; Fumitaka Kikkawa
Journal:  BMC Cancer       Date:  2007-07-27       Impact factor: 4.430

8.  Altered glutamyl-aminopeptidase activity and expression in renal neoplasms.

Authors:  Lorena Blanco; Begoña Sanz; Itxaro Perez; Clara E Sánchez; M Luz Cándenas; Francisco M Pinto; Javier Gil; Luis Casis; José I López; Gorka Larrinaga
Journal:  BMC Cancer       Date:  2014-05-30       Impact factor: 4.430

9.  Inhibitory effect of antisense aminopeptidase N (APN/CD13) cDNA transfection on the invasive potential of osteosarcoma cells.

Authors:  Akira Kido; Sabine Krueger; Carsten Haeckel; Albert Roessner
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 10.  The relationship between human coronaviruses, asthma and allergy-An unresolved dilemma.

Authors:  Maciej Chałubiński; Adrian Gajewski; Marek L Kowalski
Journal:  Clin Exp Allergy       Date:  2020-08-26       Impact factor: 5.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.